The Brucella melitensis M5-90ΔmanB live vaccine candidate is safer than M5-90 and confers protection against wild-type challenge in BALB/c mice.

[1]  D. Comerci,et al.  A T4SS Effector Targets Host Cell Alpha-Enolase Contributing to Brucella abortus Intracellular Lifestyle , 2016, Front. Cell. Infect. Microbiol..

[2]  D. Pascual,et al.  Brucellosis vaccines for livestock. , 2016, Veterinary immunology and immunopathology.

[3]  Tiansen Li,et al.  The Brucella melitensis M5-90 phosphoglucomutase (PGM) mutant is attenuated and confers protection against wild-type challenge in BALB/c mice , 2016, World journal of microbiology & biotechnology.

[4]  O. Holst,et al.  Structural Studies of Lipopolysaccharide-defective Mutants from Brucella melitensis Identify a Core Oligosaccharide Critical in Virulence* , 2016, The Journal of Biological Chemistry.

[5]  Jing Zhang,et al.  A Brucella melitensis M5-90 wboA deletion strain is attenuated and enhances vaccine efficacy. , 2015, Molecular immunology.

[6]  Antje Lindae,et al.  Expression, purification and characterization of cold shock protein A of Corynebacterium pseudotuberculosis. , 2015, Protein expression and purification.

[7]  A. Teixeira-Carvalho,et al.  Immune response triggered by Brucella abortus following infection or vaccination. , 2015, Vaccine.

[8]  Tiansen Li,et al.  A potent Brucella abortus 2308 Δery live vaccine allows for the differentiation between natural and vaccinated infection , 2014, Journal of Microbiology.

[9]  J. Gorvel,et al.  Lipopolysaccharide as a target for brucellosis vaccine design. , 2013, Microbial pathogenesis.

[10]  J. D. Palacios-Alfaro,et al.  Wildlife reservoirs of brucellosis: Brucella in aquatic environments. , 2013, Revue scientifique et technique.

[11]  B. Liu,et al.  Expression of the soybean allergenic protein P34 in Escherichia coli and its indirect ELISA detection method , 2012, Applied Microbiology and Biotechnology.

[12]  Yufei Wang,et al.  The 16MΔvjbR as an ideal live attenuated vaccine candidate for differentiation between Brucella vaccination and infection. , 2011, Veterinary microbiology.

[13]  N. H. Jazani,et al.  A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. , 2011, FEMS immunology and medical microbiology.

[14]  S. Boyle,et al.  Brucellosis: a re-emerging zoonosis. , 2010, Veterinary microbiology.

[15]  J. Solera,et al.  Chronic Brucellosis and Persistence of Brucella melitensis DNA , 2009, Journal of Clinical Microbiology.

[16]  Ruifu Yang,et al.  Comparative Proteomics Analyses Reveal the virB of B. melitensis Affects Expression of Intracellular Survival Related Proteins , 2009, PloS one.

[17]  C. Guzmán-Verri,et al.  Brucella abortus Uses a Stealthy Strategy to Avoid Activation of the Innate Immune System during the Onset of Infection , 2007, PloS one.

[18]  A. Foulkes,et al.  Treatment of Brucella-susceptible mice with IL-12 increases primary and secondary immunity. , 2006, Cellular immunology.

[19]  G. Riccardi,et al.  Protective Properties of Rifampin-Resistant Rough Mutants of Brucella melitensis , 2005, Infection and Immunity.

[20]  E. Moreno,et al.  Brucella lipopolysaccharide acts as a virulence factor. , 2005, Current opinion in microbiology.

[21]  C. Woods,et al.  Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51. , 2004, Vaccine.

[22]  T. Ficht,et al.  Brucella abortus Rough Mutants Are Cytopathic for Macrophages in Culture , 2004, Infection and Immunity.

[23]  R. Berkelman.  Human illness associated with use of veterinary vaccines. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  J. Liautard,et al.  The analysis of the intramacrophagic virulome of Brucella suis deciphers the environment encountered by the pathogen inside the macrophage host cell , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. O’Callaghan,et al.  Identification of Brucella suis Genes Affecting Intracellular Survival in an In Vitro Human Macrophage Infection Model by Signature-Tagged Transposon Mutagenesis , 2000, Infection and Immunity.

[26]  M. Corbel,et al.  WHO consultation on the development of new/improved brucellosis vaccines. 17 December 1997, Geneva, Switzerland. , 1998, Biologicals : journal of the International Association of Biological Standardization.

[27]  E. Raz,et al.  Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Mosmann,et al.  The expanding universe of T-cell subsets: Th1, Th2 and more. , 1996, Immunology today.

[29]  C. Janeway,et al.  CD4+ T Cells: Specificity and Function , 1988, Immunological reviews.

[30]  S. Elberg,et al.  Immunization against Brucella infection. VI. Immunity conferred on goats by a nondependent mutant from a streptomycin-dependent mutant strain of Brucella melitensis. , 1957, Journal of bacteriology.

[31]  E. Moreno,et al.  Rough vaccines in animal brucellosis: structural and genetic basis and present status. , 2004, Veterinary research.

[32]  C. Whitfield,et al.  Lipopolysaccharide endotoxins. , 2002, Annual review of biochemistry.

[33]  S. Elberg.  Rev 1 Brucella melitensis vaccine. Part III 1981-1995. , 1996 .